Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid
Kander Elizabeth M; Shah Manisha H; Zhou Ye; Goyal Ashima; Palmer Joshua D; Owen Dwight H; Shilo Konstantin; Patel Gopal; Raval Raju R; Gonzalez Javier; Nguyen Michele; Olek Elizabeth; Kherani Jennifer; Rothenberg S Michael; Konda Bhavana
Clinical Lung Cancer 2021
Epub 2020 Jun 18. Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid. Kander EM(1), Shah MH(1), Zhou Y(1), Goyal A(1), Palmer JD(2), Owen DH(1), Shilo K(3), Patel G(3), Raval RR(2), Gonzalez J(4), Nguyen M(5), Olek E(5), Kherani J(5), Rothenberg SM(5), Konda B(6).